HCVACC - Hepatitis c virus (hcv) : prevention and treatment of infection and disease (LIFE QUALITY) (2000-03-01 - 2004-07-31) (»add to infobox)

T. F. DAMEN, Hubert E. BLUM, Peter WIESLI, Alain MERIEUX, Patrick SABOUST, Veronique DEBISSCHOP, Henk VAN DE RUIT, Juergen KINDER, Claude GRISCELLI, Karl Peter Christian SPATH, Heather MARSHALL-HEYMAN, Gerd Rudolf PAPE, Jose Manuel ZUMAQUERO ROMERO, Aldo COSSU, Brigitte OLIVET, Rodney PHILLIPS

UNIVERSITEIT LEIDEN (NL331 - Agglomeratie Leiden en Bollenstreek) (Netherlands), ALBERT-LUDWIGS-UNIVERSITAET FREIBURG (DE131 - Freiburg im Breisgau, Stadtkreis) (Germany), BERNA BIOTECH LTD (CH021 - Bern) (Switzerland), BIOMERIEUX SA (FR716 - Rhône) (France), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR301 - Nord) (France), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR716 - Rhône) (France), FOUNDATION BIOMEDICAL PRIMATE RESEARCH CENTER (NL333 - Delft en Westland) (Netherlands), GSF - FORSCHUNGSZENTRUM FUER UMWELT UND GESUNDHEIT GMBH (DE212 - München, Kreisfreie Stadt) (Germany), INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR716 - Rhône) (France), JOHANNES GUTENBERG UNIVERSITAET MAINZ (DEB35 - Mainz, Kreisfreie Stadt) (Germany), KAROLINSKA INSTITUTET (SE010 - Stockholms län) (Sweden), LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (DE212 - München, Kreisfreie Stadt) (Germany), UNIVERSIDAD DE NAVARRA (ES220 - Navarra) (Spain), UNIVERSITA DEGLI STUDI DI BARI (ITF42 - Bari) (Italy), UNIVERSITE DE PARIS V 'RENÉ DESCARTES' (FR101 - Paris) (France), UNIVERSITY OF OXFORD (UK523 - Oxfordshire) (Great Britain)

The overall objective of this cluster is to contribute to the development of preventive and therapeutic vaccines against hepatitis C virus (HCV) infection. For this objective an in depth understanding of protective antiviral immune responses is essential by acquiring knowledge on mechanisms associated with HCV replication, assembly and fundamental knowledge on HCV specific immune responses in natural infections. A key element in the development of a vaccine is the choice of a delivery system capable to induce a humoral and/or a cellular-mediated protective immune response. The networks in this cluster proposal have strong, worldwide recognized expertise and have all parameters to monitor the planned analysis from fundamental in vitro studies to the evaluation of vaccine candidates in non-human primates. The basic strength of the Cluster is to re-unite expertise and unique systems that will allow a solid basis for the definition of clinical trials.

PERSONS (16/16)

RELATED NAVIGATION AREA(S) (4/4)